Join us for Episode 20 of Let’s Talk SADS Live on Tuesday, June 18th, at 12 p.m. Eastern! Our host Dr. Shubhayan Sanatani will be joined by experts to discuss groundbreaking gene therapy advancements for catecholaminergic polymorphic ventricular tachycardia (CPVT). We’ll explore how the patient voice plays a crucial role in these developments and the potential impact of these therapies.

Guests:

Dr. Gabriel Brooks: Dr Gabriel Brooks is a trained clinical cardiologist, and the Chief Medical Officer of Solid Biosciences, a leading precision medicines company for Neuromuscular and Cardiovascular diseases. Gabriel has been involved in the development of medicines for rare cardiovascular diseases and has been been dedicated to gene therapy development for the last 10 years leading development at 4D Molecular Therapeutics, and then leading rare cardiovascular disease development at Pfizer before moving on to Solid Biosciences.

Annie Ganot: Annie Ganot is the co-founder and Head of Patient Advocacy at Solid Biosciences, a position she has held for 10 years. Solid Biosciences is a precision medicines company focused on neuromuscular and cardiac conditions. The inspiration behind the company comes from her son’s diagnosis of Duchenne muscular dystrophy, a personal experience that fuels her passion for improving patients’ lives.

You can watch the live event on our Instagram, Facebook, Youtube, and X accounts.